Works matching IS 11738804 AND DT 2024 AND VI 38 AND IP 1
Results: 11
Acknowledgement to Referees.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s40259-023-00638-x
- Publication type:
- Article
Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 133, doi. 10.1007/s40259-023-00636-z
- By:
- Publication type:
- Article
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 61, doi. 10.1007/s40259-023-00634-1
- By:
- Publication type:
- Article
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 5, doi. 10.1007/s40259-023-00633-2
- By:
- Publication type:
- Article
Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 95, doi. 10.1007/s40259-023-00632-3
- By:
- Publication type:
- Article
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 121, doi. 10.1007/s40259-023-00630-5
- By:
- Publication type:
- Article
AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 73, doi. 10.1007/s40259-023-00629-y
- By:
- Publication type:
- Article
Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 157, doi. 10.1007/s40259-023-00628-z
- By:
- Publication type:
- Article
Outer Membrane Vesicle Vaccine Platforms.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 47, doi. 10.1007/s40259-023-00627-0
- By:
- Publication type:
- Article
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 23, doi. 10.1007/s40259-023-00626-1
- By:
- Publication type:
- Article
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 145, doi. 10.1007/s40259-023-00625-2
- By:
- Publication type:
- Article